MA39094B1 - Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers - Google Patents

Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers

Info

Publication number
MA39094B1
MA39094B1 MA39094A MA39094A MA39094B1 MA 39094 B1 MA39094 B1 MA 39094B1 MA 39094 A MA39094 A MA 39094A MA 39094 A MA39094 A MA 39094A MA 39094 B1 MA39094 B1 MA 39094B1
Authority
MA
Morocco
Prior art keywords
cancers
treatment
pharmaceutically active
additional pharmaceutically
active ingredients
Prior art date
Application number
MA39094A
Other languages
English (en)
Other versions
MA39094A1 (fr
Inventor
Sean Caenepeel
Jude Canon
Paul Hughes
Jonathan D Oliner
Richard J Rickles
Anne Y Saiki
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA39094A1 publication Critical patent/MA39094A1/fr
Publication of MA39094B1 publication Critical patent/MA39094B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La présente invention concerne une polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires, en particulier pour le traitement de cancers. L'invention a également trait à des compositions pharmaceutiques contenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers.
MA39094A 2013-11-11 2014-11-11 Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers MA39094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361902717P 2013-11-11 2013-11-11
PCT/US2014/065034 WO2015070224A2 (fr) 2013-11-11 2014-11-11 Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers

Publications (2)

Publication Number Publication Date
MA39094A1 MA39094A1 (fr) 2018-07-31
MA39094B1 true MA39094B1 (fr) 2020-06-30

Family

ID=52001089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39094A MA39094B1 (fr) 2013-11-11 2014-11-11 Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers

Country Status (30)

Country Link
US (3) US20160287569A1 (fr)
EP (2) EP4039256A1 (fr)
JP (5) JP2016535795A (fr)
KR (3) KR102473485B1 (fr)
CN (2) CN105934255A (fr)
AP (1) AP2016009243A0 (fr)
AU (3) AU2014346354A1 (fr)
BR (1) BR112016010564A2 (fr)
CA (1) CA2930244A1 (fr)
CL (1) CL2016001131A1 (fr)
DK (1) DK3068393T5 (fr)
EA (2) EA202092456A3 (fr)
ES (1) ES2916721T3 (fr)
HR (1) HRP20220718T1 (fr)
HU (1) HUE059351T2 (fr)
IL (2) IL245568B (fr)
LT (1) LT3068393T (fr)
MA (1) MA39094B1 (fr)
MX (6) MX2020013670A (fr)
MY (1) MY192088A (fr)
NZ (2) NZ720766A (fr)
PH (1) PH12016500871A1 (fr)
PL (1) PL3068393T3 (fr)
PT (1) PT3068393T (fr)
RS (1) RS63348B9 (fr)
SG (1) SG10201902429PA (fr)
SI (1) SI3068393T1 (fr)
TN (1) TN2016000176A1 (fr)
UA (1) UA120750C2 (fr)
WO (1) WO2015070224A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809366B8 (pt) 2007-03-28 2021-05-25 Harvard College polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2850166C (fr) 2011-09-27 2019-12-03 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
EP4039256A1 (fr) * 2013-11-11 2022-08-10 Amgen Inc. Thérapie combinée comprenant un inhibiteur mdm2 et dasatinib ou nilotinib pour le traitement de leucémie chronique myéloide
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
TWI711452B (zh) 2015-02-20 2020-12-01 日商第一三共股份有限公司 癌症的倂用治療法
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
JP2018528206A (ja) * 2015-08-28 2018-09-27 ノバルティス アーゲー Ｍｄｍ２阻害剤およびその組み合わせ物
WO2017037586A1 (fr) * 2015-08-28 2017-03-09 Novartis Ag Polythérapie utilisant un inhibiteur de pi3k et un inhibiteur de mdm2
WO2017200826A1 (fr) * 2016-05-16 2017-11-23 Albert Einstein College Of Medicine, Inc. Dosages et composés pour le traitement du cancer
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
MX2019008458A (es) 2017-01-17 2019-12-02 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
US20210186946A1 (en) * 2018-04-30 2021-06-24 Kartos Therapeutics, Inc. Methods of Treating Cancer
CN112804994A (zh) * 2018-05-25 2021-05-14 卡托斯医疗公司 治疗骨髓增殖性肿瘤的方法
WO2020023502A1 (fr) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et utilisations associées
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
TW202034918A (zh) * 2018-12-11 2020-10-01 美商卡托斯醫療公司 治療眼睛病況之方法及組合物
CN111434353A (zh) * 2019-02-02 2020-07-21 中国科学院上海营养与健康研究所 Ras抑制剂筛选及疗效标志物
WO2021018032A1 (fr) * 2019-07-26 2021-02-04 Ascentage Pharma (Suzhou) Co., Ltd. Composition pharmaceutique d'inhibiteur de mdm2 et son utilisation pour prévenir et/ou traiter une maladie
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
US20230218575A1 (en) * 2020-06-15 2023-07-13 Ascentage Pharma (Suzhou) Co., Ltd. Microsuspension of an mdm2 inhibitor and therapeautic applications thereof
AR123227A1 (es) * 2020-08-12 2022-11-09 Servier Pharmaceuticals Llc Terapias combinadas para su uso en el tratamiento del cáncer
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
CN115089585A (zh) * 2022-08-05 2022-09-23 中国科学院大学宁波华美医院 Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
KR20070073791A (ko) 2004-10-18 2007-07-10 암젠 인코포레이티드 티아디아졸 화합물 및 이의 사용방법
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
EP2139882B1 (fr) 2007-03-23 2013-12-25 Amgen Inc. Dérivés de quinoléine ou quinoxaline 3-substituée et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
CA2680783C (fr) 2007-03-23 2012-04-24 Amgen Inc. Composes heterocycliques et leurs utilisations
PT2137186E (pt) 2007-03-23 2016-03-30 Amgen Inc Compostos heterocíclicos e suas utilizações
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
US8557830B2 (en) 2007-06-07 2013-10-15 Amgen Inc. RAF kinase modulators and methods of use
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
EP2231661A1 (fr) 2007-12-19 2010-09-29 Amgen, Inc. Inhibiteurs de la pi3 kinase
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
EP2278973B1 (fr) 2008-04-07 2011-11-02 Amgen Inc. Amino-pyridines/pyrimidines spirocycliques et gem-disubstituées en tant qu'inhibiteurs du cycle cellulaire
WO2009155121A2 (fr) 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
EP2387570A1 (fr) 2009-01-15 2011-11-23 Amgen, Inc Thiazoles substitués par fluoroisoquinoléine et leurs méthodes d'application
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
WO2010108074A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs de pi3 kinase
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2011012037A (es) 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
EA201270051A1 (ru) 2009-06-25 2012-05-30 Амген Инк. Гетероциклические соединения и их применения
EP2445902A2 (fr) 2009-06-25 2012-05-02 Amgen, Inc Composés hétérocycliques et leurs utilisations en tant qu'inhibiteurs de l'activité des pi3k
JP2012531435A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド ＰＩ３Ｋ阻害剤としての４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン誘導体
TW201111362A (en) 2009-06-25 2011-04-01 Amgen Inc Heterocyclic compounds and their uses
EP2818170B1 (fr) 2009-09-11 2018-12-05 Amgen, Inc N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridine yl) oxy)phényl)-4-(4-méthyl-2-thiényl)-1-phthalazinamine à utiliser dans le traitement d'un cancer résistant aux agents antimitotiques
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
KR20120031734A (ko) * 2010-09-27 2012-04-04 삼성전자주식회사 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법
WO2012106299A1 (fr) * 2011-01-31 2012-08-09 Celgene Corporation Compositions pharmaceutiques d'analogues de cytidine et leurs méthodes d'utilisation
CA2850166C (fr) 2011-09-27 2019-12-03 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
WO2013144923A1 (fr) 2012-03-30 2013-10-03 Takeda Pharmaceutical Company Limited Administration d'un inhibiteur de raf et d'un inhibiteur de mek dans le traitement du mélanome
MX362896B (es) 2013-02-19 2019-02-22 Amgen Inc Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer.
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
BR112015031397A8 (pt) 2013-07-26 2018-01-30 Boehringer Ingelheim Int volasertib em combinação com decitabine para o tratamento de leucemia mieloide aguda e síndrome mielodisplásica ii.
EP4039256A1 (fr) * 2013-11-11 2022-08-10 Amgen Inc. Thérapie combinée comprenant un inhibiteur mdm2 et dasatinib ou nilotinib pour le traitement de leucémie chronique myéloide

Also Published As

Publication number Publication date
MX2022012320A (es) 2022-10-27
US20220280495A1 (en) 2022-09-08
CN105934255A (zh) 2016-09-07
JP2021004259A (ja) 2021-01-14
IL245568B (en) 2021-09-30
CA2930244A1 (fr) 2015-05-14
SI3068393T1 (sl) 2022-11-30
SG10201902429PA (en) 2019-04-29
PL3068393T3 (pl) 2022-10-03
PH12016500871A1 (en) 2016-07-04
MX2019009853A (es) 2019-10-14
EP4039256A1 (fr) 2022-08-10
AU2020201321A1 (en) 2020-03-12
MX2020013670A (es) 2022-09-30
AU2022201495A1 (en) 2022-03-24
LT3068393T (lt) 2022-08-10
DK3068393T3 (da) 2022-06-13
MX2016006025A (es) 2016-12-02
HRP20220718T1 (hr) 2022-09-30
EP3068393B9 (fr) 2022-07-20
DK3068393T5 (da) 2022-08-22
WO2015070224A2 (fr) 2015-05-14
JP2023033414A (ja) 2023-03-10
EA202092456A2 (ru) 2021-05-31
RS63348B1 (sr) 2022-07-29
US20190290630A1 (en) 2019-09-26
US10881648B2 (en) 2021-01-05
KR102305351B1 (ko) 2021-09-24
BR112016010564A2 (pt) 2017-10-10
WO2015070224A3 (fr) 2015-08-13
PT3068393T (pt) 2022-06-14
JP2016535795A (ja) 2016-11-17
MX2022008175A (es) 2022-08-15
MA39094A1 (fr) 2018-07-31
ES2916721T3 (es) 2022-07-05
HUE059351T2 (hu) 2022-11-28
NZ720766A (en) 2022-02-25
IL245568A0 (en) 2016-06-30
KR20160074012A (ko) 2016-06-27
RS63348B9 (sr) 2022-10-31
EA201690980A1 (ru) 2016-09-30
KR20220167335A (ko) 2022-12-20
JP2022009805A (ja) 2022-01-14
JP6972274B2 (ja) 2021-11-24
AP2016009243A0 (en) 2016-05-31
NZ758548A (en) 2022-02-25
UA120750C2 (uk) 2020-02-10
AU2014346354A1 (en) 2016-05-26
CL2016001131A1 (es) 2017-04-17
KR20210119550A (ko) 2021-10-05
EA036942B1 (ru) 2021-01-18
KR102473485B1 (ko) 2022-12-01
TN2016000176A1 (en) 2017-10-06
IL285646A (en) 2021-09-30
CN112933236A (zh) 2021-06-11
US20160287569A1 (en) 2016-10-06
EA202092456A3 (ru) 2021-09-30
AU2020201321B2 (en) 2022-03-10
MX2020001550A (es) 2022-04-26
MY192088A (en) 2022-07-26
EP3068393A2 (fr) 2016-09-21
JP2019142916A (ja) 2019-08-29
EP3068393B1 (fr) 2022-03-09

Similar Documents

Publication Publication Date Title
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MX2022002465A (es) Inhibidores de kras g12d.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
SA519402217B1 (ar) مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MA43876A (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201690302A1 (ru) Композиции для местного применения для лечения избыточного потоотделения и способы их применения
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201791483A1 (ru) Фармацевтическая композиция для лечения микоза
FR3074421B1 (fr) Extrait d'helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении
EA202191415A1 (ru) Комбинированная терапия, включающая ингибитор krasg12c и одно или несколько дополнительных фармацевтически активных средств, для лечения видов рака
MA46096B1 (fr) Stimulateurs sgc bicycliques fusionnés
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)